News | January 07, 2008

Brief Ischemia Episodes Create Cardioprotective Effect

January 7, 2008 - Ischemia experienced in brief episodes could protect the heart by preparing it for a heart attack, according to early findings from an animal study by researchers at the University of Cincinnati, which was published in the January issue of the American Journal of Physiology: Heart and Circulatory Physiology.

Rat hearts transfused with blood preconditioned by mini “stress tests” from reduced blood flow had significantly better reperfusion after heart attack-like ischemia than those that received a transfusion from donors that were not subjected to stress beforehand (P

Preconditioning activated a protective pathway called Janus kinase (JAK) to signal transducers and activators of transcription (STAT). The JAK-STAT pathway could offer a therapy against the damage of a heart attack.

A transfer of protection suggested that the effect was mediated by a soluble molecule released during brief periods of stress. Researchers indicated that this molecular mediator likely activates the JAK-STAT pathway.

Hearts that received effluent from preconditioned hearts but were treated with the JAK 2 inhibitor AG-490 recovered less than any other group.

Increased STAT-3 activation, reduced STAT-1 activation, and decreased expression of the pro-apoptotic protein Bax were associated with the protective effect.

Researchers do not yet know how long the cardioprotective effect lasts after a brief period of ischemia. However, "translating this phenomenon into a clinically useful tool may protect the myocardium from potential injury in a variety of settings," she said, "including acute myocardial infarction, cardiac revascularization surgery, supply/demand imbalance in congestive heart failure, and ischemia/reperfusion challenge following shock."

For more information: ajpheart.physiology.org


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now